Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Ossia M. Eichhoff(University of Zurich), Mitchell P. Levesque(Duke University), Andrea Aloia(ETH Zurich), Nina Zila(Medical University of Vienna), Annalisa Saltari(University Hospital of Zurich), Susana Pascoal(St Anna Children's Hospital), Vasanthi S. Viswanathan(Coastline Community College), Andreas Dzung(University Hospital of Zurich), Martin Distel(Primary Children's Hospital), Zsolt Balázs(University of Zurich), Michael Krauthammer(University of Zurich), Alaa Othman(University of Zurich), Corinne I. Stoffel(University of Zurich), Stuart L. Schreiber(Broad Institute), Thorsten Hornemann(University Hospital of Zurich), Gergely Karsai(University of Zurich), Jan Käsler(University Hospital of Zurich), Berend Snijder(ETH Zurich), Phil F. Cheng(University Hospital of Zurich), Judith Wenzina(Medical University of Vienna), Patrick Turko(University Hospital of Zurich), Pål Johansen(University Hospital of Zurich), Anja Irmisch(University of Zurich), Julien Mena(ETH Zurich), Luzia Briker(University Hospital of Zurich), Aizhan Tastanova(University Hospital of Zurich), Reinhard Dummer(University Hospital of Zurich), Nicola Zamboni(Scuola Internazionale Superiore di Studi Avanzati), Andrea Bileck(University of Vienna), Rebekka Wegmann(ETH Zurich), Verena Paulitschke(University Hospital of Zurich), Alexander Leitner(ETH Zurich)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Regulation of Ferroptotic Cancer Cell Death by GPX4
|Cell|2014|7.5k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k